✦ LIBER ✦

Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients

✍ Scribed by A. Åsberg; A. Humar; A. G. Jardine; H. Rollag; M. D. Pescovitz; H. Mouas; A. Bignamini; H. Töz; I. Dittmer; M. Montejo; A. Hartmann; on behalf of the VICTOR Study Group

Book ID: 114805115
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 194 KB
Volume: 9
Category: Article
ISSN: 1600-6135
DOI: 10.1111/j.1600-6143.2009.02617.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Cytomegalovirus Infection o

Treatment of Cytomegalovirus Infection or Disease in Solid Organ Transplant Recipients with Valganciclovir

✍ Jacques Fellay; Jean-Pierre Venetz; Manuel Pascual; John-David Aubert; Charles S 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB

Treatment of Cytomegalovirus Infection o

Treatment of Cytomegalovirus Infection or Disease in Solid Organ Transplant Recipients With Valganciclovir

✍ J. Fellay; J.-P. Venetz; J.-D. Aubert; C. Seydoux; M. Pascual; P.R.A. Meylan 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Oral Valganciclovir Is Noninferior to In

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

✍ A. Åsberg; A. Humar; H. Rollag; A. G. Jardine; H. Mouas; M. D. Pescovitz; D. Sga 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

Randomized controlled trial of oral ganc

Randomized controlled trial of oral ganciclovir versus intravenous ganciclovir for long-term prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients willi CMV-seropositive donors

✍ D. Winston; R.W. Busuttil 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 283 KB